EGFR and K-Ras mutations in women with lung adenocarcinoma: Implications for treatment strategy definition

Journal of Experimental and Clinical Cancer Research

Volumn 33, Issue 1, 2014, Pages

  Rotella, Virginia ^a   Fornaro, Lorenzo ^a   Vasile, Enrico ^b   Tibaldi, Carmelo ^c   Boldrini, Laura ^d   Chella, Antonio ^b   D'Incecco, Armida ^c   Cirigliano, Giovanna ^a   Chioni, Aldo ^e   Lupi, Cristiana ^b   Sensi, Elisa ^b   Ginocchi, Laura ^b   Giovannelli, Simona ^a   Pennucci, Maria Cristina ^f   Fontanini, Gabriella ^d   Baldini, Editta ^a  

^a San Luca Hospital   (Italy)

^b UNIVERSITY HOSPITAL OF PISA   (Italy)

^c Ospedale Civile   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e MISERICORDIA HOSPITAL   (Italy)

^f Ospedale di Carrara   (Italy)

Author keywords

Chemotherapy; EGFR; K Ras; Lung adenocarcinoma; Tyrosine kinase inhibitors

Indexed keywords

CISPLATIN; EPIDERMAL GROWTH FACTOR; ERLOTINIB; GEMCITABINE; NAVELBINE; PACLITAXEL; PEMETREXED; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR; KRAS PROTEIN, HUMAN; ONCOPROTEIN; RAS PROTEIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER REGRESSION; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CODON; CONTROLLED STUDY; DISEASE ASSOCIATION; EGFR GENE; EXON; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; ITALIAN (CITIZEN); LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; ONCOGENE K RAS; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PYROSEQUENCING; REAL TIME POLYMERASE CHAIN REACTION; RETROSPECTIVE STUDY; SALVAGE THERAPY; TREATMENT OUTCOME; TREATMENT RESPONSE; WILD TYPE; ADENOCARCINOMA; GENETICS; LUNG NEOPLASMS; METASTASIS; MIDDLE AGED; MORTALITY; MUTATION; PATHOLOGY; PROGNOSIS; VERY ELDERLY;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; FEMALE; HUMANS; LUNG NEOPLASMS; MIDDLE AGED; MUTATION; NEOPLASM METASTASIS; NEOPLASM STAGING; PROGNOSIS; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RETROSPECTIVE STUDIES; SALVAGE THERAPY;

EID: 84965184366     PISSN: None     EISSN: 17569966     Source Type: Journal    
DOI: 10.1186/s13046-014-0077-6     Document Type: Article

References (22)

1. Ciardiello F, Tortora G: EGFR antagonists in cancer treatment. N Engl J Med 2008, 358:1160-1174.
2. Capdevila J, Elez E, Macarulla T, Ramos FJ, Ruiz-Echarri M, Tabernero J: Anti-epidermal growth factor receptor monoclonal antibodies in cancer treatment. Cancer Treat Rev 2009, 35:354-363.
3. Harris TJ, McCormick F: The molecular pathology of cancer. Nat Rev Clin Oncol 2010, 7:251-265.
4. Schmoll HJ, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, van de Nordlinger B, Velde CJ, Balmana J, Regula J, Nagtegaal ID, Beets-Tan RG, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne CH, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard JY, El Ghazaly H, Gallardo J, Garin A, Glynne-Jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A: ESMO ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Ann Oncol 2012, 23:2479-2516.
5. Douillard JY, Oliner KS, Siena S, Tabernero J, Burkes R, Barugel M, Humblet Y, Bodoky G, Cunningham D, Jassem J, Rivera F, Kocákova I, Ruff P, Lasiñska-Morawiec M, Smakal M, Canon JL, Rother M, Williams R, Rong A, Wiezorek J, Sidhu R, Patterson SD: Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. NEnglJMed2013, 369:1023-1034.
6. Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin 2013, 63:11-30.
7. Patel JD: Lung cancer in women. J Clin Oncol 2005, 14:3212-3218.
8. Cufer T, Ovcaricek T, O'Brien ME: Systemic therapy of advanced non-small cell lung cancer: major-developments of the last 5-years. Eur J Cancer 2013, 49:1216-1225.
9. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabárbara P, Seymour L, National Cancer Institute of Canada Clinical Trials Group: Erlotinib in previously treated non-small-cell lung cancer. NEnglJMed2005, 353:123-132.
10. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN,Christiani DC, Settleman J, Haber DA: Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004, 350:2129-2139.
11. Roengvoraphoj M, Tsongalis GJ, Dragnev KH, Rigas JR: Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non-small cell lung cancer: focus on epidermal growth factor receptor mutation testing and mutation-positive patients. Cancer Treat Rev 2013, 39:839-850.
12. Zhang Q, Dai HH, Dong HY, Sun CT, Yang Z, Han JQ: EGFR mutations and clinical outcomes of chemotherapy for advanced non-small cell lung cancer: A meta-analysis. Lung Cancer 2014, 85:339-345.
13. Kris MG, Johnson BE, Kwiatkowski DJ, Iafrate AJ, Wistuba II, Aronson SL, Engelman JA, Shyr Y, Khuri FR, Rudin CM, Garon EB, Pao W, Schiller JH, Haura EB, Shirai K, Giaccone G, Berry LD, Kugler K, Minna JD, Bunn PA: Identification of driver mutations in tumor specimens from 1,000 patients with lung adenocarcinoma: The NCI's Lung Cancer Mutation Consortium (LCMC) [abstract]. J Clin Oncol 2011, 29, CRA7506.
14. Roberts PJ, Stinchcombe TE: KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013, 31:1112-1121.
15. Vasan N, Boyer JL, Herbst RS: A RAS renaissance: emerging targeted therapies for KRAS-mutated non-small cell lung cancer. Clin Cancer Res 2014, 20:3921-3930.
16. Loriot Y, Mordant P, Deutsch E, Olaussen KA, Soria JC: Are RAS mutations predictive markers of resistance to standard chemotherapy? Nat Rev Clin Oncol 2009, 6:528-534.
17. Linardou H, Dahabreh IJ, Kanaloupiti D, Siannis F, Bafaloukos D, Kosmidis P, Papadimitriou CA, Murray S: Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer. Lancet Oncol 2008, 9:962-972.
18. Mao C, Qiu LX, Liao RY, Du FB, Ding H, Yang WC, Li J, Chen Q: KRAS mutations and resistance to EGFR-TKIs treatment in patients with non-small cell lung cancer: a meta-analysis of 22 studies. Lung Cancer 2010, 69:272-278.
19. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG: New guidelines to evaluate the response to treatment in solid tumours. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
20. Bauml J, Mick R, Zhang Y, Watt CD, Vachani A, Aggarwal C, Evans T, Langer C: Determinants of survival in advanced non-small-cell lung cancer in the era of targeted therapies. Clin Lung Cancer 2013, 14:581-591.
21. European Medicines Agency: http://www.ema.europa.eu/ema/ [date last accessed: December 10, 2013].
22. Garassino M, Rulli E, Marabese M, Torri V, Longo F, Ganzinelli M, Farina G, Veronese S, Marsoni S, Broggini M: Prognostic and predictive role of KRAS mutations in patients with advanced non small cell lung cancer treated with docetaxel or erlotinib as second line treatment in the TAILOR trial [abstract]. Eur J Cancer 2013, 2:32.